Up-regulated MSI2 is associated with more aggressive chronic myeloid leukemia
Up-regulated MSI2 is associated with more aggressive chronic myeloid leukemia
复制标题
DOI：
10.3109/10428194.2014.981175
复制
发表时间：
2015-07-01
影响因子：
2.6
通讯作者：
le Coutre, Philipp
中科院分区：
文献类型：
--
作者：
Kaeda, Jaspal;Ringel, Frauke;le Coutre, Philipp
更好地了解触发慢性粒细胞白血病进展的事件对于优化慢性粒细胞白血病 (CML) 的临床管理至关重要。我们试图验证转录后调节因子 Musashi 2 (MSI2) 表达的增加与进展和预后相关。对 152 名 CML 患者的筛查显示，诊断时处于慢性期 (CP) 的 CML 患者中 MSI2 显着降低 (p < 0.0001)，但发现正常对照组与治疗的 CP 期 CML 患者之间没有显着差异。此外，晚期疾病 (AD) CML 患者的 MSI2 显着增加 (p < 0.0001)。此外，我们的人类造血细胞系数据表明 MSI2 和 BCR-ABLI mRNA 表达是相关的。然而，这些数据对早期关于 MSI2 通过 NUMB-NOTCH 信号传导影响 HES1 表达的报道提出了质疑。
A better understanding of events triggering chronic myeloid leukemia progression is critical for optimized clinical management of chronic myeloid leukemia (CML). We sought to validate that increased expression of Musashi 2 (MSI2), a post-transcription regulator, is associated with progression and prognosis. Screening of 152 patients with CML showed that MSI2 was significantly decreased among patients with CML in chronic phase (CP) at diagnosis (p < 0.0001), but found no significant difference between the normal control group and treated patients with CML in CP. Moreover MSI2 was significantly increased (p < 0.0001) in patients with advance disease (AD) CML. Furthermore, our human hematopoietic cell line data imply that MSI2 and BCR-ABLI mRNA expression are correlated. However, these data cast a doubt on earlier reports that MSI2 effects HES1 expression via NUMB-NOTCH signaling.